GETT
17.5.2021 13:02:09 CEST | Business Wire | Press release
Gett, the leading corporate Ground Transportation Management (GTM) platform and B2B marketplace, is supporting the UK government Department for Transport and its Global Travel Taskforce with the safe return of international travel.
Gett’s ground transportation B2B marketplace now provides its clients with updates from the UK Government’s ‘traffic light’ system, supporting partners and users worldwide for the safe return of international travel. On its platform, Gett will update users with information on testing, quarantining, and travel restrictions to allow passengers access to information and government guidelines in relation to the next phase of re-opening the UK economy. This initiative supports Gett’s desire to assist employers to satisfy their duty of care obligations towards their employees, by providing users with access to information for safe travel.
As announced by the UK government on 9 April 2021, the ‘traffic light’ system applies different risk-based restrictions for passengers returning to the UK. Those travelling from ‘green’ countries require a negative Covid-19 test prior to departure but do not have to isolate when coming back into the UK, whilst travellers returning from ‘amber’ countries similarly require a negative pre-departure Covid-19, but also must isolate at home for 10 days upon their return and get a PCR test on days 2 and 8. Travellers from ‘red’ countries additionally require a negative Covid-19 test prior to departure and must isolate in specified hotels for 10 days.
Currently serving more than a quarter of Fortune 500 companies, Gett‘s unique position as a B2B marketplace for ground transportation management makes Gett a valuable partner for the UK government’s reopening of corporate travel. Gett has recently strengthened its international offering, with further expansion into the US market through the continued growth of global partner fleets. This includes the previously announced partnership with e-fleet operator Curb Mobility , joining a portfolio of existing corporate fleet, ride-hailing, taxi, and limo providers, including Lyft and Ola .
Andrew Verbitsky, Deputy CEO of Gett, commented: “The safe resumption of international travel is essential to restarting the corporate travel sector and supporting and enabling global economic recovery. Gett, as the leading corporate Ground Transportation Management (GTM) platform and B2B marketplace, is uniquely positioned to be a valued partner in this important milestone for the UK and global economy. Gett is committed to the safe resumption of corporate travel for its B2B clients and their employees.”
About Gett
Gett is a technology platform solely focused on corporate Ground Transportation Management (GTM), a market worth $79.6B globally. https://bit.ly/2SEIV3M
Gett is the GTM category leader, serving over a quarter of the Fortune 500 companies.
Gett’s cloud-based software aggregates existing transportation providers onto a single platform, helping businesses manage all of their ground transportation spend. Additionally, Gett expands companies’ coverage by connecting them to a grid of transportation providers globally.
Gett organises corporate fleet, ride-hailing, taxi, and limo providers on one platform, optimising the entire employee experience, from booking and riding to invoicing and analytics, saving businesses time and money.
Founded in 2010 and headquartered in London, Gett has raised more than $750M in funding to date, including more than $300M from the Volkswagen Group.
-ENDS-
View source version on businesswire.com: https://www.businesswire.com/news/home/20210517005435/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom